Advertisement


Related Videos

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Advertisement